Related Experiment Video
Updated: Aug 12, 2026
Expression, Detergent Solubilization, and Purification of a Membrane Transporter, the MexB Multidrug Resistance Protein
Published on: December 3, 2010
Multidrug resistance
1Clinical Pharmacology Branch, National Cancer Institute, Bethesda, MD 20892.
Abstract:
The ability of malignant cells to develop resistance to cytotoxic drugs poses a major obstacle to the ultimate success of cancer therapy. While some mechanisms of resistance allow cells to survive exposure to a single agent, the phenomenon of multidrug resistance (MDR) confers upon cells the ability to withstand exposure to lethal doses of many structurally unrelated antineoplastic agents. MDR has been strongly linked to the overexpression of a membrane-associated glycoprotein, P-glycoprotein, which appears to play a role in drug efflux. However, several lines of evidence suggest that other mechanisms of resistance are involved in MDR; biochemical similarities observed in a human breast cancer cell line after the acquisition of MDR and in carcinogen-induced rat preneoplastic hepatic nodules indicate that changes in regulation of phase I and phase II drug-metabolizing enzymes may also play a role in MDR. An atypical pattern of MDR has been characterized and related to altered topoisomerase activity. Improvement in current cancer chemotherapy may be achieved by interfering with the regulation and expression of mechanisms of MDR.
Insights
Cancer cells can resist chemotherapy through multidrug resistance (MDR). Understanding MDR mechanisms, like P-glycoprotein and drug-metabolizing enzymes, is key to improving cancer treatment effectiveness.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Malignant cells developing resistance to cytotoxic drugs is a significant challenge in cancer therapy.
- Multidrug resistance (MDR) allows cancer cells to survive lethal doses of various antineoplastic agents.
- P-glycoprotein overexpression is linked to MDR, potentially through drug efflux.
Purpose of the Study:
- To explore the multifaceted mechanisms underlying multidrug resistance (MDR) in cancer.
- To investigate the role of drug-metabolizing enzymes and topoisomerase activity in MDR.
- To identify potential therapeutic targets for overcoming MDR in cancer chemotherapy.
Main Methods:
- Analysis of biochemical similarities between MDR cancer cell lines and carcinogen-induced preneoplastic hepatic nodules.
- Characterization of atypical MDR patterns associated with altered topoisomerase activity.
- Review of evidence linking P-glycoprotein and drug-metabolizing enzymes to MDR.
Main Results:
- Evidence suggests that altered regulation of phase I and phase II drug-metabolizing enzymes may contribute to MDR.
- Atypical MDR has been identified and linked to changes in topoisomerase activity.
- While P-glycoprotein is implicated, other resistance mechanisms are also involved in MDR.
Conclusions:
- Multidrug resistance (MDR) involves complex mechanisms beyond P-glycoprotein.
- Targeting drug-metabolizing enzymes and topoisomerase activity could offer new strategies to combat MDR.
- Interfering with MDR mechanisms may enhance the efficacy of current cancer chemotherapy.
More Related Videos
07:35Demonstrating a Multi-drug Resistant Mycobacterium tuberculosis Amplification Microarray
Published on: April 25, 2014
05:06Characterizing Multidrug Efflux Systems in Acinetobacter baumannii Using an Efflux-Deficient Bacterial Strain and a Single-Copy Gene Expression System
Published on: January 5, 2024
Related Concept Videos
01:36Mismatch Repair
00:57Antibiotic Selection
02:56Treatment Resistant Cancers
01:30Development of Antibiotic Resistance
01:25Mechanism of Antibiotic Resistance in MRSA
01:25Clinical Significance of Antibiotic Resistance